Presented last week during ASCO’s Genitourinary Cancers Symposium,Translating Evidence to Multidisciplinary Care, 08 – 10 February (San Francisco, USA), latest results from a retrospective and international study were presented by first author, VHIO’s Joaquin Mateo, Principal Investigator of Prostate Cancer Translational Research.
Joaquin and colleagues showed for the first time that patients with inherited DNA repair mutations benefit from standard therapies in a similar way to other metastatic prostate cancer patients. Timed to coincide with his presentation at the meeting, findings were published ahead of print in European Urology. In an interview with ecancerTV, Joaquin discusses the relevance and implications of this study.
To discover more about what Joaquin had to say on the ground in San Francisco click on the video below:
